Avance Clinical, a leading full-service Contract Research Organization (CRO), has announced three pivotal Memorandums of Understanding (MOUs) with major clinical sites in South Korea, signed during the KoNECT 2024 conference. These partnerships mark a significant milestone in Avance Clinical’s strategy to expand its high-quality, agile clinical trial services across the Asia-Pacific region.

Avance Clinical’s CEO, Yvonne Lungershausen, and Asia Regional Director, Jessica Han, formalized these partnerships with CHA University Bundang Medical Center, Korea University Medicine, and Dong-A University Hospital, broadening the CRO’s capabilities in early-phase trials and advancing global therapeutic research.

“These new MOUs further strengthen our mission to provide world-class services to international biotech clients,” said Lungershausen. “As Avance Clinical continues to grow, these partnerships with respected institutions will enhance our ability to offer flexible, efficient, and high-quality clinical trial services in the Asia-Pacific region.”

Jessica Han added, “South Korea’s advanced healthcare infrastructure offers an ideal environment for clinical trials. These partnerships solidify our collaborations and grant clients seamless access to top-tier clinical trial sites and patient populations.”

This development reflects Avance Clinical's commitment to the Asia-Pacific market, reinforced through the partnerships signed at KoNECT 2024, co-hosted by the Korea National Enterprise for Clinical Trials (KoNECT) and the Ministry of Health and Welfare (MOHW).